What's exciting to me about drug repurposing is that it closes the feedback loop for validating AI-driven predictions. In this clip from the Cure. AI-Drug Discovery event, I explain that for-profit companies need to navigate supporting an AI platform to generate predictions and the lengthy process of traditional drug development. They must continue to support their AI functions without knowing if they have created something of value. In drug repurposing, however, we can validate these AI predictions quickly, directly feeding the outcomes back into the platform. This immediate validation is crucial, ensuring that our AI functions are constantly learning and improving, ultimately leading to more effective treatments for patients. #DrugRepurposing #AI #biotech #pharma
This is the craziest competitive advantage of EveryCure. Their ability to ideate and feed AI data years ahead of others is a game-changer. It's like everyone else is digging tunnels with pickaxes, while they have dynamite
Don’t forget that if drug repurposing is to achieve statistical significance in efficacy for heterogeneous complex diseases (eg. solid tumors), predictive biomarkers should be incorporated into clinical evaluation as early as possible, especially given our rapidly evolving understanding of molecular drivers of disease.
Co-founder and CEO, Unravel Biosciences | Termeer Fellow
7moThis is such an important insight that we at Unravel Biosciences also make to investors who are all about new molecules. Yes, the value for both patients and investors likely lies there, but you have to get there first. Existing molecules can be an incredibly unfair advantage! We have had several clinical success stories using existing molecules, all within a couple months, that would have been impossible if we had focused only on new drugs.